---
input_text: Advancement Opportunities and Endeavor of Innovative Targeted Therapies
  for Small Cell Lung Cancer. Small cell lung cancer (SCLC) is an intractable disease
  with rapid progression and high mortality, presenting a persistent obstacle impeding
  clinical management. Although recent advancements in immunotherapy have enhanced
  the response rates of platinum-based chemotherapy regimens, the emergence of acquired
  resistance invariably leads to recurrence and metastasis. Consequently, there is
  an urgent necessity to explore novel therapeutic targets and optimize existing treatment
  strategies. This article comprehensively reviews the currently available therapeutic
  modalities for SCLC. It delves into the immunologic prognostic implications by analyzing
  selected immune-related signatures. Moreover, it conducts an in-depth exploration
  of the molecular subtyping of SCLC and the associated molecular pathways to identify
  potential therapeutic targets. Specifically, the focus is on clinical interventions
  targeting delta-like ligand 3 (DLL3), elucidating its resistance mechanisms and
  demonstrating its notable antitumor efficacy. Furthermore, the study examines the
  mechanisms of chimeric antigen receptor (CAR) T and antibody-drug conjugate (ADC),
  covering resistance issues and strategies for optimizing resistance management,
  with particular emphasis being placed on analyzing the prospects and clinical value
  of CAR T therapy in the context of SCLC. Moreover, the effectiveness of poly ADP-ribose
  polymerase and ataxia telangiectasia and rad3/checkpoint kinase 1 inhibitors is
  discussed and underscores the advantages of combining these inhibitors with standard
  chemotherapy to combat chemoresistance and enhance the antitumor effects of immunotherapies.
  Overall, this study investigates emerging strategies for targeted therapies and
  optimized combination regimens to overcome resistance in SCLC and highlights future
  strategies for new therapeutic technologies for SCLC.
raw_completion_output: |-
  primary_disease: Small cell lung cancer (SCLC)

  medical_actions: Immunotherapy; Chemotherapy; Targeted therapy, specifically delta-like ligand 3 (DLL3) inhibitors; Chimeric antigen receptor (CAR) T therapy; Antibody-drug conjugate (ADC) therapy; Poly ADP-ribose polymerase (PARP) inhibitors; Ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1) inhibitors; Combination regimens to combat chemoresistance

  symptoms: Rapid progression; High mortality; Recurrence; Metastasis

  chemicals: Delta-like ligand 3 (DLL3); Poly ADP-ribose polymerase (PARP); Ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1)

  action_annotation_relationships: Immunotherapy (with Chemotherapy) TREATS recurrence IN Small cell lung cancer (SCLC); Targeted therapy (with DLL3 inhibitors) TREATS recurrence IN Small cell lung cancer (SCLC); CAR T therapy TREATS recurrence IN Small cell lung cancer (SCLC); ADC therapy TREATS recurrence IN Small cell lung cancer (SCLC); PARP inhibitors TREATS chemoresistance IN Small cell lung cancer (SCLC); ATR/CHK1 inhibitors TREATS chemoresistance IN Small cell lung cancer (SCLC); Combination regimens TREATS chemoresistance IN Small cell lung cancer (SCLC)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Combination regimens TREATS chemoresistance IN Small cell lung cancer (SCLC)

  ===

extracted_object:
  primary_disease: MONDO:0008433
  medical_actions:
    - Immunotherapy
    - MAXO:0000647
    - Targeted therapy, specifically delta-like ligand 3 (DLL3) inhibitors
    - Chimeric antigen receptor (CAR) T therapy
    - Antibody-drug conjugate (ADC) therapy
    - Poly ADP-ribose polymerase (PARP) inhibitors
    - Ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1) inhibitors
    - Combination regimens to combat chemoresistance
  symptoms:
    - HP:0003678
    - High mortality
    - Recurrence
    - Metastasis
  chemicals:
    - Delta-like ligand 3 (DLL3)
    - CHEBI:62913
    - Ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1)
  action_annotation_relationships:
    - subject: Immunotherapy
      predicate: TREATS
      object: recurrence
      qualifier: MONDO:0008433
      subject_qualifier: with Chemotherapy
      subject_extension: Chemotherapy
    - subject: Targeted therapy
      predicate: TREATS
      object: recurrence
      qualifier: MONDO:0008433
      subject_qualifier: with DLL3 inhibitors
      subject_extension: DLL3 inhibitors
    - subject: <CAR T therapy>
      predicate: <TREATS>
      object: <recurrence>
      qualifier: MONDO:0008433
      subject_qualifier: <None>
      object_qualifier: <None>
      subject_extension: <CAR T therapy>
      object_extension: <None>
    - subject: MAXO:0001298
      predicate: TREATS
      object: recurrence
      qualifier: MONDO:0008433
      subject_extension: CHEBI:18198
    - subject: PARP inhibitors
      predicate: TREATS
      object: chemoresistance
      qualifier: MONDO:0008433
      subject_extension: PARP inhibitors
    - subject: ATR/CHK1 inhibitors
      predicate: TREATS
      object: chemoresistance
      qualifier: MONDO:0008433
      subject_extension: ATR/CHK1 inhibitors
    - subject: Combination regimens
      predicate: TREATS
      object: chemoresistance
      qualifier: MONDO:0008433
named_entities:
  - id: MONDO:0005086
    label: Renal cell carcinoma
  - id: MONDO:0003060
    label: Biliary tract cancer (BTC)
  - id: CHEBI:175901
    label: Gemcitabine
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: MONDO:0008840
    label: Ataxia Telangiectasia
  - id: MAXO:0010030
    label: Bone Marrow Transplantation
  - id: MAXO:0001001
    label: Gene Therapy
  - id: CHEBI:166830
    label: Acetyl-DL-leucine
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:4462
    label: Dexamethasone sodium phosphate
  - id: CHEBI:133021
    label: venetoclax
  - id: HP:0002721
    label: Immunodeficiency
  - id: HP:0002073
    label: progressive cerebellar ataxia
  - id: HP:0002013
    label: vomiting
  - id: HP:0002315
    label: headache
  - id: CHEBI:27899
    label: cisplatin
  - id: HP:0001903
    label: Anemia
  - id: HP:0001873
    label: Thrombocytopenia
  - id: HP:0001875
    label: Neutropenia
  - id: CHEBI:231342
    label: Ceralasertib
  - id: CHEBI:31355
    label: Carboplatin
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation
  - id: MONDO:0005184
    label: Pancreatic ductal adenocarcinoma (PDAC)
  - id: HP:0020174
    label: Drug resistance
  - id: MAXO:0000011
    label: Physical therapy
  - id: HP:0001251
    label: Ataxia
  - id: MONDO:0010150
    label: Head and neck squamous cell carcinomas (HNSCC)
  - id: MAXO:0000014
    label: Radiotherapy (RT)
  - id: HP:0010280
    label: Oral mucositis
  - id: HP:0002015
    label: Dysphagia
  - id: MONDO:0008876
    label: Bloom Syndrome (BS)
  - id: HP:0001510
    label: growth retardation
  - id: HP:0011793
    label: malignancies
  - id: MONDO:0004992
    label: Cancer
  - id: HP:0002664
    label: Cancer
  - id: CHEBI:27656
    label: Camptothecin (CPT)
  - id: CHEBI:63632
    label: Topotecan
  - id: CHEBI:4911
    label: Etoposide
  - id: CHEBI:231344
    label: Talazoparib
  - id: CHEBI:231616
    label: M4344
  - id: MONDO:0008433
    label: Small-cell lung cancer (SCLC)
  - id: HP:0030357
    label: Small-cell lung cancer (SCLC)
  - id: MONDO:0003778
    label: Inborn Errors of Immunity (IEI)
  - id: HP:0033141
    label: Severe SARS-CoV-2 infection
  - id: MAXO:0001017
    label: Vaccination
  - id: CHEBI:22907
    label: Bleomycin (BLM)
  - id: MONDO:0005494
    label: Triple-negative breast cancer (TNBC)
  - id: CHEBI:9555
    label: 6-thioguanine
  - id: CHEBI:4659
    label: Disulfiram
  - id: CHEBI:28694
    label: Cu
  - id: CHEBI:83766
    label: Olaparib
  - id: HP:0002894
    label: pancreatic cancer
  - id: MONDO:0005192
    label: Pancreatic Cancer
  - id: MONDO:0007254
    label: Breast Cancer
  - id: MAXO:0000127
    label: Genetic testing
  - id: HP:0003002
    label: Breast Cancer
  - id: MONDO:0008903
    label: lung cancer
  - id: MAXO:0001298
    label: therapy
  - id: MONDO:0005070
    label: Tumors
  - id: MAXO:0001394
    label: Oral administration
  - id: MONDO:0036501
    label: Refractory Cancer
  - id: CHEBI:45863
    label: Paclitaxel
  - id: MONDO:0018177
    label: Glioblastoma
  - id: MAXO:0000004
    label: Surgery
  - id: HP:0012174
    label: Glioblastoma
  - id: MONDO:0009807
    label: Osteosarcoma
  - id: MAXO:0001525
    label: Intravenous administration
  - id: CHEBI:132992
    label: radiosensitizers
  - id: MONDO:0005575
    label: colorectal cancer
  - id: CHEBI:62913
    label: poly (ADP-ribose) polymerase (PARP) inhibitors
  - id: HP:0010310
    label: Chylothorax
  - id: CHEBI:3638
    label: Chloroquine
  - id: CHEBI:27563
    label: Arsenic
  - id: CHEBI:229924
    label: pifithrin-alpha (PFTalpha)
  - id: CHEBI:29678
    label: Sodium arsenite (NaAsO2)
  - id: CHEBI:41774
    label: Tamoxifen
  - id: MONDO:0004986
    label: Bladder cancer
  - id: HP:0009725
    label: Bladder cancer
  - id: MONDO:0968974
    label: Large B-Cell Lymphoma (LBCL)
  - id: MAXO:0000381
    label: Lymph node biopsy
  - id: CHEBI:64357
    label: Rituximab
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: CHEBI:44185
    label: Methotrexate
  - id: CHEBI:8382
    label: Prednisone
  - id: MONDO:0005623
    label: AT (Autoimmune Thyroiditis)
  - id: MONDO:0008315
    label: Prostate Cancer
  - id: CHEBI:4672
    label: Docetaxel
  - id: HP:0012125
    label: Prostate Cancer
  - id: CHEBI:50914
    label: PI3K inhibitors
  - id: CHEBI:34936
    label: di-phenoxy acetamide (DPA) analogs
  - id: CHEBI:25555
    label: Compound DPA (7n)
  - id: HP:0000988
    label: rash
  - id: CHEBI:31348
    label: capecitabine
  - id: CHEBI:16044
    label: MET
  - id: HP:0100526
    label: Lung cancer
  - id: MONDO:0019600
    label: Xeroderma pigmentosum (XP)
  - id: CHEBI:131808
    label: Thymidine dimers
  - id: CHEBI:28300
    label: Glutamine
  - id: CHEBI:16856
    label: Glutathione
  - id: CHEBI:16810
    label: Alpha-ketoglutarate
  - id: HP:0000657
    label: Oculomotor apraxia
  - id: HP:0001266
    label: Choreoathetosis
  - id: CHEBI:4806
    label: Epigallocatechin-3-gallate (EGCG)
  - id: CHEBI:16240
    label: H2O2
  - id: CHEBI:229722
    label: RP-3500
  - id: CHEBI:135702
    label: Belotecan
  - id: CHEBI:229661
    label: Omaveloxolone
  - id: CHEBI:8863
    label: riluzole
  - id: MAXO:0000058
    label: pharmacotherapy
  - id: MONDO:0100339
    label: Friedreich ataxia
  - id: MONDO:0005140
    label: Epithelial ovarian cancer
  - id: HP:0002018
    label: Nausea
  - id: HP:0012378
    label: Fatigue
  - id: HP:0002039
    label: Anorexia
  - id: MONDO:0005233
    label: Non-small cell lung cancer
  - id: HP:0030358
    label: Non-small cell lung cancer
  - id: CHEBI:3077
    label: Betamethasone
  - id: CHEBI:30884
    label: Glucocorticoids (GCs)
  - id: MONDO:0024331
    label: Colorectal Cancer (CRC)
  - id: MONDO:0005061
    label: Lung adenocarcinoma (LUAD)
  - id: HP:0030078
    label: Lung adenocarcinoma
  - id: HP:0025318
    label: epithelial ovarian cancer
  - id: CHEBI:46345
    label: 5-fluorouracil
  - id: CHEBI:31941
    label: Oxaliplatin
  - id: CHEBI:80630
    label: Irinotecan
  - id: CHEBI:131509
    label: lysine-specific histone demethylase 1a inhibitors
  - id: MONDO:0017361
    label: Chronic restraint stress (CRS)
  - id: CHEBI:16865
    label: GABA
  - id: MONDO:0006047
    label: Pancreatic Adenocarcinoma
  - id: CHEBI:76649
    label: Astaxanthin (AST)
  - id: CHEBI:40968
    label: Astaxanthin
  - id: HP:0004377
    label: hematologic malignancies
  - id: HP:0100521
    label: thymic tumors
  - id: MAXO:0000068
    label: transplantation
  - id: MONDO:0007256
    label: Hepatocellular carcinoma (HCC)
  - id: MONDO:0002691
    label: Liver cancer
  - id: HP:0008322
    label: Abnormal mitochondrial morphology
  - id: CHEBI:8064
    label: Phenformin
  - id: CHEBI:228209
    label: KU-55933
  - id: HP:0002896
    label: liver cancer
  - id: CHEBI:156203
    label: Topoisomerase II inhibitors
  - id: CHEBI:28748
    label: Doxorubicin
  - id: MAXO:0000448
    label: Surgical resection
  - id: CHEBI:16991
    label: DNA
  - id: HP:0003678
    label: Rapid progression
  - id: CHEBI:18198
    label: ADC
